Study guide
12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies
ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring
1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal
2 Chapter 2: Assessment Foundations & Lifespan Considerations
2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)
3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation
3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles
4 Chapter 4: Cardiovascular Disorders
4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease
5 Chapter 5: Respiratory Disorders
5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules
6 Chapter 6: HEENT & Allergic/Immunologic Disorders
6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency
7 Chapter 7: Endocrine & Metabolic Disorders
7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism
8 Chapter 8: Gastrointestinal & Hepatic Disorders
8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening
9 Chapter 9: Renal, Urological & Men's Health
9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction
10 Chapter 10: Musculoskeletal & Rheumatologic Disorders
10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes
11 Chapter 11: Neurological & Psychiatric Disorders
11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care
12 Chapter 12: Dermatologic, Hematologic & Infectious Disease
12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies
13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care
13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions
14 Chapter 14: Gynecologic & Women's Health
14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)
15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination
15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment
16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement
16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics
12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies
Key Takeaways Explain This Topic AI
Diagnostic approach to anemia begins with the Mean Corpuscular Volume (MCV: microcytic <80 fL, normocytic 80-100 fL, macrocytic >100 fL) and the Reticulocyte Production Index (RPI: >2% indicates hyperproliferative marrow response to hemolysis or blood loss; <2% indicates hypoproliferative nutrient deficiency, marrow failure, or systemic suppression).
Microcytic anemia (TAILS: Thalassemia, Anemia of chronic disease, Iron deficiency, Lead toxicity, Sideroblastic) is most commonly Iron Deficiency Anemia (serum ferritin <30 ng/mL, high TIBC, low TSAT <20%, high RDW); in adult males and postmenopausal females, unexplained iron deficiency anemia is gastrointestinal bleeding from colorectal or gastric malignancy until proven otherwise by colonoscopy and upper endoscopy.
Megaloblastic macrocytic anemia (oval macrocytes + pathognomonic hypersegmented neutrophils) is caused by Vitamin B12 or Folate deficiency; Vitamin B12 deficiency produces both anemia and irreversible neurological degeneration (subacute combined degeneration of the spinal cord), with elevated Methylmalonic Acid (MMA) and Homocysteine, whereas Folate deficiency produces anemia with elevated Homocysteine but NORMAL MMA and NO neurological deficits.
Heparin-Induced Thrombocytopenia (HIT Type II) is an immune-mediated prothrombotic emergency caused by IgG autoantibodies against Heparin-Platelet Factor 4 (PF4) complexes, presenting with a >=50% drop in platelet count 5-10 days after heparin exposure; clinical management demands immediate cessation of all heparin and initiation of a non-heparin direct thrombin inhibitor (argatroban, bivalirudin) or fondaparinux (never give warfarin until platelets recover to >=150,000/mcL).
Thrombotic Thrombocytopenic Purpura (TTP) is a life-threatening medical emergency caused by severe deficiency of the von Willebrand factor-cleaving protease ADAMTS13 (<10%), characterized by microangiopathic hemolytic anemia with schistocytes, severe thrombocytopenia, fluctuating neurological deficits, fever, and renal impairment; requires emergent Therapeutic Plasma Exchange (PLEX) and systemic corticosteroids (platelet transfusions are strictly contraindicated).
Last updated: August 2026
Hematologic Disorders: Anemias, Leukopenia & Coagulopathies
Hematologic abnormalities are encountered daily in adult and geriatric primary care, ranging from asymptomatic mild laboratory anomalies discovered on routine screening to fulminant, life-threatening oncologic and thrombohemorrhagic emergencies. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) , clinical mastery requires systematic interrogation of complete blood count (CBC) indices, peripheral blood smears, iron kinetics, bone marrow proliferative responses, and the coagulation cascade.
1. Algorithmic Diagnostic Approach to Anemias
Anemia is defined by the World Health Organization (WHO) as Hemoglobin (Hb) < 13.0 g/dL <13.0\text{ g/dL} < 13.0 g/dL in adult men and < 12.0 g/dL <12.0\text{ g/dL} < 12.0 g/dL in non-pregnant adult women . Initial classification relies on the Mean Corpuscular Volume (MCV) and the bone marrow's regenerative capacity measured by the Reticulocyte Production Index (RPI) . +---------------------------------------------------------------------------------------------------+
- | ALGORITHMIC CLASSIFICATION OF ANEMIAS |
- | |
- | [INITIAL CBC: HEMOGLOBIN / HEMATOCRIT REDUCED] |
- | | |
- | v |
- | [EVALUATE MEAN CORPUSCULAR VOLUME (MCV)] |
- | / | \ |
- | v v v |
- | MICROCYTIC (MCV <80 fL) NORMO CYTIC (MCV 80-100 fL) MACROCYTIC (MCV >100 fL) |
- | * Differential (TAILS): * CHECK RETICULOCYTE INDEX: * EVALUATE PERIPHERAL SMEAR: |
- | - Thalassemia - RPI >2% (Hyperproliferative): - Megaloblastic (Hypersegmented |
- | - Anemia of Chronic * Hemolysis (Warm AIHA, neutrophils + oval macrocytes): |
- | Disease (ACD) Cold agglutinin, G6PD, * Vitamin B12 Deficiency |
- | - Iron Deficiency Sickle cell, MAHA/TTP) * Folate (B9) Deficiency |
- | - Lead Poisoning * Acute blood hemorrhage - Non-Megaloblastic (Round macrocytes)|
- | - Sideroblastic - RPI <2% (Hypoproliferative): * Chronic Alcoholism / Cirrhosis |
- | * Early Iron / B12 / Folate * Hypothyroidism |
- | * Anemia of Chronic Disease * Myelodysplastic Syndromes (MDS) |
- | * Chronic Kidney Dis (Low EPO) * Reticulocytosis |
- | * Aplastic Anemia / Marrow inv * Medications (Hydroxyurea) |
- +---------------------------------------------------------------------------------------------------+
- The Reticulocyte Production Index (RPI)
Raw reticulocyte percentages overestimate marrow response in anemia because the total RBC pool is reduced. The AGPCNP calculates the Corrected Reticulocyte Count and RPI : Corrected Reticulocyte Count (%) = Observed Reticulocyte % × ( Patient’s Hematocrit Normal Hematocrit (45) ) \text{Corrected Reticulocyte Count (\%)} = \text{Observed Reticulocyte \%} \times \left(\frac{\text{Patient's Hematocrit}}{\text{Normal Hematocrit (45)}}\right) Corrected Reticulocyte Count (%) = Observed Reticulocyte % × ( Normal Hematocrit (45) Patient’s Hematocrit ) Reticulocyte Production Index (RPI) = Corrected Reticulocyte Count Maturation Correction Factor (1.0 to 2.5 based on Hct) \text{Reticulocyte Production Index (RPI)} = \frac{\text{Corrected Reticulocyte Count}}{\text{Maturation Correction Factor (1.0 to 2.5 based on Hct)}} Reticulocyte Production Index (RPI) = Maturation Correction Factor (1.0 to 2.5 based on Hct) Corrected Reticulocyte Count
RPI > 2.0 % >2.0\% > 2.0% : Adequate marrow response; indicates accelerated erythrocyte destruction ( Hemolysis ) or acute hemorrhage.
RPI < 2.0 % <2.0\% < 2.0% : Inadequate hypoproliferative marrow response; indicates substrate deficiency (iron, B12, folate), lack of erythropoietin stimulation (CKD), marrow suppression/damage, or chronic inflammation.
2. Microcytic Anemias (MCV <80 fL): Differential Diagnosis +---------------------------------------------------------------------------------------------------+
- | MICROCYTIC ANEMIAS: IRON KINETICS & DIFFERENTIAL |
- | |
- | PARAMETER IRON DEFICIENCY (IDA) THALASSEMIA TRAIT ANEMIA CHRONIC DIS (ACD) |
- | --------------------------------------------------------------------------------------------- |
- | Serum Ferritin LOW (<30 ng/mL; NORMAL to HIGH NORMAL to ELEVATED (acute |
- | <15 is diagnostic) (normal iron stores) phase reactant; trapped iron) |
- | Serum Iron LOW NORMAL LOW |
- | TIBC HIGH (>400 mcg/dL) NORMAL LOW to NORMAL (<250 mcg/dL) |
- | Transferrin Sat LOW (<16% - 20%) NORMAL LOW to NORMAL (15% - 25%) |
- | RDW HIGH (>15%; anisocytosis)NORMAL (homogeneous size)NORMAL to mildly elevated |
- | RBC Count LOW HIGH (>5.5 million/mcL; LOW to NORMAL |
- | microcytic polycythemia) |
- | Mentzer Index > 13 < 13 Variable |
- | (MCV / RBC count) |
- | Hemoglobin Normal HbA, A2, F Beta-Thal: HbA2 >3.5% Normal HbA, A2, F |
- | Electrophoresis Alpha-Thal: Normal |
- +---------------------------------------------------------------------------------------------------+
- Iron Deficiency Anemia (IDA): Etiology, Clinical Findings & Management
Etiologies:
Adult Males & Postmenopausal Females: Gastrointestinal blood loss until proven otherwise! Mandatory evaluation with Colonoscopy and Esophagogastroduodenoscopy (EGD) to exclude occult colorectal carcinoma, gastric adenocarcinoma, peptic ulcer disease, or angiodysplasias.
Premenopausal Females: Menorrhagia / abnormal uterine bleeding, pregnancy/lactation.
Malabsorption: Celiac disease, prior Roux-en-Y gastric bypass, Helicobacter pylori gastritis, chronic high-dose PPI use.
Physical Signs: Pallor (conjunctival, palmar), fatigue, exertional dyspnea, koilonychia (spoon nails) , angular cheilitis, atrophic glossitis, pica (compulsive craving for non-nutritive substances: pagophagia [ice], geophagia [clay/dirt], amylophagia [starch]), restless legs syndrome, and Plummer-Vinson syndrome (triad of microcytic anemia, esophageal webs with dysphagia, and atrophic glossitis).
Pharmacological Treatment:
Oral Iron: Ferrous Sulfate 325 mg (65 mg elemental iron) once daily or on alternate days (alternate-day dosing enhances intestinal iron absorption by preventing hepcidin upregulation and reduces GI side effects). Take on an empty stomach with Vitamin C (ascorbic acid 500 mg) to enhance acidic absorption; avoid co-administration with calcium, antacids, PPIs, dairy, tea, or coffee. Continue oral therapy for 3 to 6 months after normalization of hemoglobin to replenish tissue ferritin stores.
Intravenous Iron (Ferric carboxymaltose, Iron sucrose): Indicated for oral iron intolerance, severe malabsorption (Celiac, bariatric surgery), active inflammatory bowel disease, chronic kidney disease on hemodialysis, or rapid replacement needs.
Thalassemia Syndromes
Beta-Thalassemia Minor (Trait): Heterozygous mutation in beta-globin gene on chromosome 11. Manifests as mild microcytic anemia (Hb 10–12 g/dL) with profound microcytosis (MCV 55–75 fL), elevated RBC count ( > 5.5 × 10 12 / L >5.5\times 10^{12}/\text{L} > 5.5 × 1 0 12 / L ), normal RDW, and Mentzer Index < 13 <13 < 13 . Confirmatory test: Hemoglobin Electrophoresis revealing elevated Hemoglobin A 2 A_2 A 2 ( > 3.5 % >3.5\% > 3.5% ) and elevated HbF.
Alpha-Thalassemia Trait: Deletion of 2 alpha-globin genes on chromosome 16. Hemoglobin electrophoresis in adults is completely normal ; definitive diagnosis requires alpha-globin gene DNA testing.
Critical Board Warning: Never prescribe empiric iron therapy to patients with thalassemia trait unless co-existing iron deficiency is proven by low ferritin! Administering iron to thalassemia patients causes iatrogenic iron overload ( hemosiderosis ).
Anemia of Chronic Disease (ACD / Anemia of Inflammation)
Pathogenesis: Driven by Hepcidin , a hepatic peptide upregulated by inflammatory cytokines (principally IL-6 ). Hepcidin binds to and degrades ferroportin (the iron efflux channel on enterocytes and reticuloendothelial macrophages), blocking intestinal iron absorption and trapping iron inside macrophage storage pools, depriving developing erythroid precursors of iron.
Management: Treat the underlying chronic inflammatory, infectious, or malignant condition. In chronic kidney disease, administer Erythropoiesis-Stimulating Agents (ESAs: Epoetin alfa, Darbepoetin alfa) when Hb < 10 g/dL \text{Hb} < 10\text{ g/dL} Hb < 10 g/dL , maintaining target Hb between 10.0 and 11.5 g/dL (targeting Hb > 11.5 g/dL \text{Hb} > 11.5\text{ g/dL} Hb > 11.5 g/dL increases risks of stroke, venous thromboembolism, and cardiovascular mortality). Ensure iron repletion (ferritin > 100 ng/mL >100\text{ ng/mL} > 100 ng/mL , TSAT > 20 % >20\% > 20% ) before initiating ESAs.
3. Macrocytic Anemias (MCV >100 fL): Megaloblastic vs. Non-Megaloblastic +---------------------------------------------------------------------------------------------------+
- | MEGALOBLASTIC ANEMIAS: BIOCHEMICAL & CLINICAL PROFILE |
- | |
- | FEATURE VITAMIN B12 (COBALAMIN) DEFICIENCY FOLATE (VITAMIN B9) DEFICIENCY |
- | --------------------------------------------------------------------------------------------- |
- | Pathophysiology Impaired DNA synthesis; defective Impaired DNA synthesis; defective |
- | conversion of homocysteine -> met purine/thymidylate synthesis. |
- | and methylmalonyl-CoA -> succinyl Stores deplete in 3 to 4 MONTHS! |
- | Stores last 3 to 5 YEARS! |
- | |
- | Common Causes Pernicious Anemia (anti-IF/anti- Inadequate dietary intake (alcoholism, |
- | parietal cell Ab), Gastrectomy, elderly tea-and-toast diet), malabsorp-|
- | terminal ileal disease (Crohn's), tion (Celiac), medications: METHOTREX- |
- | Strict Vegans, METFORMIN, PPIs. ATE, Trimethoprim, Phenytoin. |
- | |
- | Neurological Signs PRESENT & PROGRESSIVE: ABSENT! |
- | Subacute Combined Degeneration No spinal cord or peripheral nerve |
- | (SCD: posterior column vibratory / degeneration. |
- | proprioception loss, spasticity, |
- | ataxia, "megaloblastic madness"). |
- | |
- | Peripheral Smear Oval macrocytes + HYPERSEGMENTED Oval macrocytes + HYPERSEGMENTED |
- | NEUTROPHILS (>=5 lobes in >=5%). NEUTROPHILS (>=5 lobes in >=5%). |
- | |
- | Methylmalonic Acid ELEVATED (>0.4 mcmol/L) NORMAL |
- | (MMA) |
- | |
- | Homocysteine ELEVATED ELEVATED |
- | |
- | First-Line Therapy Cyanocobalamin 1000 mcg IM daily Oral Folic Acid 1 to 5 mg PO daily. |
- | x 1 wk -> weekly x 4 wks -> monthly Always rule out B12 deficiency first! |
- | (or high-dose oral 1000-2000 mcg/d). |
- +---------------------------------------------------------------------------------------------------+
- The Folate Trap & Neurological Risk
If a patient with occult Vitamin B12 deficiency is mistakenly treated with high-dose Folate monotherapy , the hematologic anemia will resolve because folate bypasses the enzymatic block in DNA synthesis, but the neurological degeneration (Subacute Combined Degeneration of the spinal cord) will rapidly progress to irreversible paraplegia and dementia . The AGPCNP must always verify Vitamin B12 levels before or concurrent with initiating folate therapy.
4. Normocytic Hemolytic Anemias & Smear Morphologies +---------------------------------------------------------------------------------------------------+
- | HEMOLYTIC ANEMIAS: LABORATORY HALLMARKS & TAXONOMY |
- | |
- | [HALLMARKS OF ACTIVE HEMOLYSIS] |
- | - Elevated Reticulocyte Production Index (RPI >2%) |
- | - Elevated Lactate Dehydrogenase (LDH) & Elevated Indirect (Unconjugated) Bilirubin |
- | - Decreased / Absent Serum Haptoglobin (haptoglobin binds free intravascular hemoglobin) |
- | - Peripheral Smear Abnormalities (Schistocytes, Spherocytes, Bite cells, Target cells) |
- | | |
- | v |
- | [DIRECT ANTIGLOBULIN TEST (DAT / COOMBS TEST)] |
- | / \ |
- | v v |
- | DAT POSITIVE: IMMUNE-MEDIATED DAT NEGATIVE: NON-IMMUNE |
- | 1. Warm AIHA (IgG mediated at 37°C): 1. Microangiopathic (MAHA / Schistocytes): |
- | - Extravascular splenic hemolysis; - TTP, HUS, DIC, Mechanical valves. |
- | Spherocytes on smear; triggered by - High shear stress fragments RBCs. |
- | CLL, SLE, drugs (penicillin, ceftriaxone). 2. Enzymatic Defect: |
- | - First-line: Oral Prednisone (1 mg/kg/day). - G6PD Deficiency: X-linked; oxidative |
- | 2. Cold Agglutinin Disease (IgM mediated <37°C): stress (fava beans, sulfa, dapsone); |
- | - Intravascular/extravascular hemolysis; Heinz bodies & BITE CELLS (degmacytes). |
- | triggered by Mycoplasma pneumoniae, EBV. 3. Hemoglobinopathy: |
- | - Acrocyanosis; keep patient warm; Rituximab. - Sickle Cell Disease (HbSS): sickle cells,|
- | - (Steroids and splenectomy are INEFFECTIVE!). Howell-Jolly bodies (autosplenectomy). |
- +---------------------------------------------------------------------------------------------------+
- 5. Leukopenia, Oncologic Hematology & Multiple Myeloma
- Neutropenia & Febrile Neutropenia Oncologic Protocol
Absolute Neutrophil Count (ANC): ANC = Total WBC × ( % Segmented Neutrophils + % Band Neutrophils 100 ) \text{ANC} = \text{Total WBC} \times \left(\frac{\%\text{Segmented Neutrophils} + \%\text{Band Neutrophils}}{100}\right) ANC = Total WBC × ( 100 % Segmented Neutrophils + % Band Neutrophils )
Severity: Mild (1000–1500/mcL), Moderate (500–1000/mcL), Severe ( < 500 / mcL <500/\text{mcL} < 500/ mcL or predicted nadir < 500 <500 < 500 ).
Febrile Neutropenia Definition: Single oral temperature ≥ 38.3 ∘ C \ge 38.3^\circ\text{C} ≥ 38. 3 ∘ C ( 101 ∘ F 101^\circ\text{F} 10 1 ∘ F ) or sustained ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C ( 100.4 ∘ F 100.4^\circ\text{F} 100. 4 ∘ F ) for > 1 hour >1\text{ hour} > 1 hour in a patient with ANC < 500 / mcL \text{ANC} < 500/\text{mcL} ANC < 500/ mcL .
Emergency Protocol: ONCOLOGIC EMERGENCY. Administer empiric, broad-spectrum, antipseudomonal monotherapy within 60 minutes of presentation : IV Cefepime (2 g q8h) , Piperacillin-tazobactam (4.5 g q6h) , or Meropenem (1 g q8h) . Add IV Vancomycin if hemodynamic instability, central catheter infection, or pneumonia is present.
Chronic Leukemias: CLL vs. CML +---------------------------------------------------------------------------------------------------+
- | CHRONIC LEUKEMIAS COMPARATIVE PROFILE |
- | |
- | FEATURE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CHRONIC MYELOGENOUS LEUKEMIA (CML) |
- | --------------------------------------------------------------------------------------------- |
- | Epidemiology Most common leukemia in Western Adults age 40 - 60 years |
- | adults; median age 70 years (15% of adult leukemias) |
- | Cytogenetics Deletions 13q14, 11q, 17p (p53) PHILADELPHIA CHROMOSOME t(9;22)(q34;q11)|
- | BCR-ABL1 fusion tyrosine kinase gene |
- | Peripheral Smear Absolute mature lymphocytosis Dramatic leukocytosis (>100,000/mcL) |
- | (>5000/mcL) + SMUDGE CELLS with FULL MYELOID SPECTRUM (myelocytes,|
- | ("basket cells"); Coombs (+) AIHA. metamyelocytes, blasts <2%, basophilia)|
- | Clinical Signs Painless generalized lymphadenopathy,Massive splenomegaly, abdominal full- |
- | hepatosplenomegaly, fatigue. ness, hypermetabolic fever/sweats. |
- | Treatment Approach Asymptomatic early stage: WATCHFUL Targeted TYROSINE KINASE INHIBITORS |
- | WAITING (active surveillance); (TKIs: Imatinib, Dasatinib, Nilotinib).|
- | Targeted agents: BTK inhibitors |
- | (Ibrutinib, Acalabrutinib). |
- +---------------------------------------------------------------------------------------------------+
- Multiple Myeloma: The CRAB Diagnostic Tetrad
Clonal proliferation of malignant plasma cells in bone marrow producing monoclonal immunoglobulin ( M -protein M\text{-protein} M -protein , most commonly IgG in 55% or IgA in 20%):
C - Hypercalcemia: Serum calcium > 11.0 mg/dL >11.0\text{ mg/dL} > 11.0 mg/dL , caused by osteoclast-activating factors (RANKL).
R - Renal Insufficiency: Serum creatinine > 2.0 mg/dL >2.0\text{ mg/dL} > 2.0 mg/dL , caused by toxic light-chain cast nephropathy (myeloma kidney).
A - Anemia: Normocytic normochromic anemia ( Hb < 10 g/dL \text{Hb} < 10\text{ g/dL} Hb < 10 g/dL ) due to bone marrow plasma cell infiltration.
B - Bone Lytic Lesions: "Punched-out" osteolytic lesions on skeletal survey/CT, pathological fractures, severe unremitting back pain.
Diagnostic Workup: Serum Protein Electrophoresis ( SPEP - monoclonal M-spike), Urine Protein Electrophoresis ( UPEP - Bence Jones proteinuria), Serum Free Light Chain (FLC) ratio, bone marrow biopsy ( > 10 % >10\% > 10% clonal plasma cells), Rouleaux formation on peripheral blood smear (RBCs stacked like coins), and markedly elevated ESR ( > 100 mm/h >100\text{ mm/h} > 100 mm/h ).
6. Coagulopathies, Platelet Disorders & Anticoagulation +---------------------------------------------------------------------------------------------------+
- | PLATELET & COAGULATION DISORDERS MATRIX |
- | |
- | DISORDER PATHOPHYSIOLOGY & CLINICAL SIGNS LABORATORY FINDINGS MANAGEMENT PROTOCOL |
- | --------------------------------------------------------------------------------------------- |
- | Immune Autoantibodies (IgG) against Isolated THROMBO- Asymptomatic & plt>30k:|
- | Thrombocytopenia platelet GPIIb/IIIa -> splenic CYTOPENIA (<30,000);Observe. Plt <30,000 |
- | (ITP) destruction. Petechiae, purpura, normal PT/INR, aPTT,or bleeding: Oral |
- | epistaxis, mucosal bleeding. normal smear. Prednisone or IVIG. |
- | |
- | Heparin-Induced IgG autoantibodies against >=50% DROP in plt IMMEDIATELY STOP ALL |
- | Thrombocytopenia HEPARIN-PF4 COMPLEX -> platelet count 5-10 days HEPARIN! Start non- |
- | (HIT Type II) activation -> PROTHROMBOTIC CRISIS!post-heparin. Anti- heparin Direct Thrombin|
- | Venous/arterial thrombosis (DVT/PE).PF4 ELISA / SRA (+).Inhibitor (Argatroban).|
- | |
- | Thrombotic Severe deficiency of ADAMTS13 Thrombocytopenia + EMERGENT THERAPEUTIC |
- | Thrombocytopenic protease (<10%) -> ultra-large MAHA (SCHISTOCYTES) PLASMA EXCHANGE (PLEX) |
- | Purpura (TTP) vWF multimer microvascular clots. + Normal PT and aPTT+ Corticosteroids. |
- | Pentad: MAHA, Plt low, Neuro signs,(rules out DIC!). NEVER GIVE PLATELETS! |
- | Fever, Renal dysfunction. ADAMTS13 <10%. |
- | |
- | Disseminated Systemic uncontrolled activation PROLONGED PT/INR & Treat underlying cause;|
- | Intravascular of coagulation -> consumptive aPTT; Low FibrinogenCryoprecipitate (if |
- | Coagulation (DIC) coagulopathy and lethal bleeding. (<100 mg/dL); High fibrinogen <100), FFP, |
- | Triggers: Sepsis, trauma, APL. D-Dimer; Plt low. platelet transfusions. |
- +---------------------------------------------------------------------------------------------------+
- Oral Anticoagulant Monitoring & Reversal Agents
Warfarin (Coumadin): Inhibits Vitamin K Epoxide Reductase (VKORC1), blocking synthesis of Factors II, VII, IX, X, and Proteins C and S. Monitored via PT/INR (Target INR 2.0–3.0 for non-valvular atrial fibrillation, DVT, PE; 2.5–3.5 for mechanical mitral valves). Reversal: Oral/IV Vitamin K1 (Phytonadione) + 4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra) for life-threatening bleeding.
Direct Oral Anticoagulants (DOACs):
Direct Factor Xa Inhibitors: Apixaban (Eliquis), Rivaroxaban (Xarelto), Edoxaban (Savaysa). Reversal Agent: Andexanet alfa (Andexxa) .
Direct Thrombin (Factor IIa) Inhibitor: Dabigatran (Pradaxa). Reversal Agent: Idarucizumab (Praxbind) .
7. Board-Yield Summary & Clinical Pearls +---------------------------------------------------------------------------------------------------+
- | ANCC AGPCNP CLINICAL EXAM PEARLS |
- | |
- | - Any new, unexplained Iron Deficiency Anemia in an adult male or postmenopausal female is |
- | Gastrointestinal Malignancy until proven otherwise! Schedule Colonoscopy and EGD. |
- | |
- | - Macrocytic Anemia with Hypersegmented Neutrophils = Megaloblastic Anemia. Check both B12 and |
- | Folate, as well as Methylmalonic Acid (MMA). Elevated MMA confirms Vitamin B12 deficiency! |
- | Never treat B12 deficiency with Folate alone, as irreversible Subacute Combined Degeneration |
- | of the spinal cord will progress. |
- | |
- | - Thalassemia Trait produces marked microcytosis (MCV 55-75) with mild anemia, high RBC count, |
- | normal ferritin, and Mentzer Index <13. Never prescribe iron therapy to Thalassemia trait! |
- | |
- | - Suspected Heparin-Induced Thrombocytopenia (HIT): Stop ALL heparin immediately and switch to |
- | Argatroban or Fondaparinux. Never initiate Warfarin until platelet counts recover to >=150,000|
- | to prevent catastrophic warfarin-induced microvascular skin necrosis. |
- | |
- | - TTP is a medical emergency requiring immediate Therapeutic Plasma Exchange (PLEX) and |
- | corticosteroids. Platelet transfusions are STRICTLY CONTRAINDICATED (fuels microvascular clots).|
- | |
- | - Multiple Myeloma CRAB Criteria: HyperCalcemia, Renal insufficiency, Anemia, Bone lytic lesions.|
- | Diagnosed with SPEP (M-spike), UPEP (Bence Jones light chains), and bone marrow biopsy. |
- +---------------------------------------------------------------------------------------------------+